Table 1

Key details of the patients’ diagnosis and treatment

Date	Disease stage	Treatment
4-Year old girl
August 2013 to 2015 (home country)	Diagnosis of retroperitoneal NB, stage 4 (INSS), MYCN amplified First CR	Chemotherapy according to HR-NBL1/SIOPEN (rapid COJEC, TVD) HD chemotherapy with busulfan/melphalan and ASCT Two tumor resections in May 2014 and July 2014 Local radiotherapy to the lumbar region Immunotherapy with dinutuximab beta and IL-2
January 2017 to November 2017 (home country)	First relapse, localized advanced PR	Tumor resection Chemotherapy according to the RIST trial, partly with bevacizumab Second HD chemotherapy with thiotepa/cyclophosphamide and ASCT Second radiotherapy
December 2017 to September 2018	PR PR followed by PD	Immunotherapy with dinutuximab beta in combination with chemotherapy courses from trial NB2004 (N5, N6) Immunotherapy with dinutuximab beta in combination with irinotecan/temozolomide
October 2018 to August 2019	PD Second CR in May 2019	Immunotherapy with dinutuximab beta and nivolumab
August 2019 to March 2020	Persistent second complete remission (CR)	None
17-Year-old young man
April 2010 to July 2010	Diagnosis of left adrenal NB, stage 2 (INSS), MYCN non-amplified First CR	Tumor surgery Chemotherapy according to trial NB2004 (2x N5, 2x N6, composition see above)
July 2011 to July 2012	First relapse, local PD in July 2012	Chemotherapy according to the RIST trial (composition see above) Tumor resection, one course of postsurgical cyclophosphamide Immunotherapy with dinutuximab beta and IL-2
July 2012–October 2012	PD Second CR	Chemotherapy according to trial NB2004 (2x N8) Tumor resection
February 2014–July 2014	Second relapse, local Third complete remission	Tumor resection Radiotherapy Systemic therapy declined
June 2018 to May 2019	Third relapse, metastatic PR followed by PD	Chemotherapy according to trial NB2004 (N5/N6 courses) Tumor resection (nephrectomy and adrenalectomy left) Local radiotherapy mIBG-therapy
June 2019 to ongoing	PD PR	Immunotherapy with DB and nivolumab

ASCT, autologous stem cell transplantation; CR, complete remission; DB, dinutuximab beta; HD, high dose; IL-2, interleukin 2; INSS, International Neuroblastoma Staging System; mIBG, metaiodobenzylguanidine; N5, cisplatin, etoposide, vindesine; N6, vincristine, dacarbacine, ifosfamide, doxorubicin; N8, topotecan, cyclophosphamide, etoposide; NB, neuroblastoma; NB2004, neuroblastoma 2004 protocol (Germany); PD, progressive disease; PR, partial remission; Rapid COJEC, carboplatin, etoposide, cisplatin, cyclophosphamide; RIST, sirolimus, irinotecan, dasatinib, temozolomide; TVD, topotecan, vincristine, doxorubicin.